University College, London
Single-pill amlodipine/atorvastatin reduces both BP and cholesterol
Published in Pharma Law Weekly, August 16th, 2005
According to a report from England, "Single-pill amlodipine besylate/atorvastatin calcium (Caduet, Pfizer Inc., NY, USA) is the first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidemia (DYS)."
M.R. Cowie of University College in London wrote, "The benefits of lowering blood pressure (BP) in patients with HTN and lowering cholesterol in patients with DYS are well known and well studied. However, worldwide, many patients with HTN have concomitant DYS, which places them at greater risk for cardiovascular disease...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2005-08-16)
More Articles from Pharma Law Weekly
- AlphaRx, Inc.
Antibiotic development program uses nanoparticle delivery platform - Amrad
U.S. patent granted for asthma treatment - Bristol-Myers Squibb Company
Agreement signed for sale of U.S., Canadian consumer medicines business - Cardinal Health, Inc.
Prescription drug benefit is on the way for patients with limited income - Consumers Union
Voluntary advertising plan won't cut it, consumer group says - Dey, LP
Pharma company reaches settlement with Connecticut on pricing litigation - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
